Case Report: R-CHOP Induction for Unresectable Castleman Disease

A 2026 case report details a patient with an 8.3×5.5 cm mediastinal hyaline-vascular unicentric Castleman disease (HV-UCD) tumor. Four cycles of R-CHOP chemoimmunotherapy achieved over 50% tumor shrinkage, enabling safe surgical resection and 12-month disease-free survival. The dataset provides evidence for using short-course R-CHOP as a bridge-to-surgery for high-risk, initially unresectable HV-UCD.

Use Cases

• Evaluating tumor response metrics (e.g., >50% shrinkage) to R-CHOP therapy in HV-UCD
• Assessing surgical outcomes (R0 resection, 12-month disease-free survival) following neoadjuvant chemoimmunotherapy
• Studying high-risk anatomical features (tumor encasing pulmonary artery/bronchus) in mediastinal Castleman disease

Strengths

• Provides a detailed, novel clinical case report for a rare disease (hyaline-vascular unicentric Castleman disease)
• Includes specific, quantitative clinical outcomes (8.3×5.5 cm tumor, >50% shrinkage, 12-month disease-free survival)
• Dataset is openly licensed (CC-BY-4.0) and available on multiple platforms

Limitations

• Dataset is a single case report, limiting statistical power and generalizability
• Column names and row counts are not provided, obscuring the dataset's internal structure
• The reported last update date (2026-03-21) is in the future, indicating a potential metadata error

Provenance

Source

Author: Jianyong Ding

Collection Method

Clinical case report

Time Range

Covers a treatment and follow-up period culminating in a 12-month outcome, reported in 2026

Freshness

Last updated 2026-03 21 09:03:47

Geography

null